This website is for Israeli Healthcare Professionals only

HematoCast ערוץ הפודקאסטים הרשמי של AbbVie אונקולוגיה ישראל.

כאן תוכלו להאזין להמטואונקולוגים המובילים בתחומם אשר יציגו בפניכם את המחקרים העדכניים ביותר וכל מה שחשוב שתהיו מעודכנים בו.

האזנה נעימה!

{{currentVideo.name}}
{{currentVideo.name}}

{{currentVideo.description}}


{{currentVideo.long_description}}


{{currentVideo.name}}
{{currentVideo.name}}

{{currentVideo.description}}


{{currentVideo.long_description}}


  

{{currentVideo.name}}
{{currentVideo.name}}

{{currentVideo.description}}


{{currentVideo.long_description}}


{{currentVideo.name}}
{{currentVideo.name}}

{{currentVideo.description}}


{{currentVideo.long_description}}


References:

1. Courtney DiNardo, Keith Pratz, Panayiotis Panayiotidis et al. The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. Abstract P510. Presentation during EHA 2022. 
2. Courtney D. DiNardo, M.D., Brian A. Jonas, M.D., Ph.D., Vinod Pullarkat et, al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 2020; 383:617-629 
3. Bushra Tbakhi, MD, Kristen O’Dwyer, MD et al. The VIALE-C Trial: Venetoclax and Low-dose Cytarabine in Older Patients With AML. The Hematologist (2020) 17 (5)
4. Ofir Wolach, Jacqueline S Garcia, Pankit Vachhani et al. Transfusion independence among newly diagnosed acute myeloid leukemia patients receiving venetoclax-based combinations vs. Other therapies: results from the AML real world evidence (ARC) initiative. Presentation during EHA2022
5. Courtney D. DiNardo, M.D., Brian A. Jonas, M.D., Ph.D., Vinod Pullarkat et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 2020; 383:617-629
6. Arizona Manda, Bertrand Marquess Anz, Christopher Benton et. al. Efficacy and safety of venetoclax in combination with azacytidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia. Journal of Clinical Oncology 2022, volume 40, issue 16.
7. Othman Al-Sawaf, Can Zhang, Sandra Robrecht, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized cll14 study. Presentation during EHA2022
8. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236
9. Paula Cramer, Moritz Fürstenau, Adam Giza et al. Retreatment with venetoclax after venetoclax, obinutuzumab +/- ibrutinib: pooled analysis of 13 patients with chronic lymphocytic leukemia (cll) treated in gcllsg trials. Presentation during EHA2022
10. Barbara Eichhorst, Carsten Niemann, Arnon Kater, et al. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (cll): pfs co-primary endpoint of the randomized phase 3 gaia/cll13 trial. Oral presentation, EHA Congress June 2022
11. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236
12. Lu P, et al. Blood Cancer J. 2021;11:39; 2. Deng J, et al. Leukemia. 2017;31:2075-2084
13. Herman ES, et al. Clin Cancer Res. 2015;21:4642-4651
14. Burger JA, et al. Leukemia. 2020;34:787-798
15. Shanafelt T, et al. N Engl J Med. 2019;381:432-443
16. Cervantes-Gomez F, et al. Clin Cancer Res. 2015;21:3705-3715
17. Kater AP, et al. Blood Adv. 2021 Sep 23 [Epub ahead of print]
18. Haselager MV, et al. Blood. 2020;136:2918-2926
19. Slinger E, et al. Leukemia. 2017;31:2601-2607
20. Wierda WG, et al. Leukemia. 2021 Jun 24 [Epub ahead of print]
21. Kater AP, et al. J Clin Oncol. 2019;37:269-277

 

המידע והתוכן באתר זה מיועדים לצוותים רפואיים בעלי רישיון ישראלי.
הסרטונים עלולים להכיל מידע על תכשירים בפיתוח ו/או מוצרים לא רשומים בישראל.

 IL-VEN-220008 | November 2022